Warning: The NCBI web site requires JavaScript to function. more...
What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs.
Moore RA, Derry S, McQuay HJ, Paling J.
Arthritis Res Ther. 2008;10(1):R20. Epub 2008 Feb 7. Review.
Related citations
Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
Moore RA, Derry S, McQuay HJ.
BMC Musculoskelet Disord. 2007 Aug 3;8:73.
Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC.
Drug Saf. 2008;31(2):143-58.
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group.
BMJ. 2009 Jul 14;339:b2538. doi: 10.1136/bmj.b2538.
Review of the cardiovascular safety of COXIBs compared to NSAIDS.
Moodley I.
Cardiovasc J Afr. 2008 Mar-Apr;19(2):102-7. Review.
Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA, Derry S, Phillips CJ, McQuay HJ.
BMC Musculoskelet Disord. 2006 Oct 20;7:79. Review.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.
Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C, Chan AT, Tramontano AC, Gazelle GS.
Ann Pharmacother. 2006 Jun;40(6):1052-63. Epub 2006 May 23.
NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Lanas A, Ferrandez A.
Chin J Dig Dis. 2006;7(3):127-33. Review.
How to advise aspirin use in patients who need NSAIDs.
Sopena F, Lanas A.
Curr Pharm Des. 2007;13(22):2248-60. Review.
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P, Henry D.
JAMA. 2006 Oct 4;296(13):1633-44. Epub 2006 Sep 12. Review.
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C.
BMJ. 2006 Jun 3;332(7553):1302-8.
Cardiovascular complications of non-steroidal anti-inflammatory drugs.
Fosslien E.
Ann Clin Lab Sci. 2005 Autumn;35(4):347-85. Review.
Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ, Islam K.
J Physiol Pharmacol. 2008 Aug;59 Suppl 2:117-33. Review.
Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
Lehmann FS, Beglinger C.
Curr Top Med Chem. 2005;5(5):449-64. Review.
Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
Joshi GP, Gertler R, Fricker R.
Anesth Analg. 2007 Dec;105(6):1793-804, table of contents. Review.
Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases.
Scheiman JM.
Drugs. 2006;66 Suppl 1:15-21; discussion 29-33. Review.
[Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
van den Bemt BJ, Benraad HB, Rasker JJ.
Ned Tijdschr Geneeskd. 2007 May 12;151(19):1062-7. Review. Dutch.
Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs.
Laine L, Smith R, Min K, Chen C, Dubois RW.
Aliment Pharmacol Ther. 2006 Sep 1;24(5):751-67. Review.
Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.
Weberschock TB, Müller SM, Boehncke S, Boehncke WH.
Arch Dermatol Res. 2007 Jul;299(4):169-75. Epub 2007 May 11. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on